Bu web sitesi, size mümkün olan en iyi kullanıcı deneyimini sunabilmek için çerezleri kullanır. Çerez bilgileri tarayıcınızda saklanır ve web sitemize döndüğünüzde sizi tanımak ve ekibimizin web sitesinin hangi bölümlerini en ilginç ve yararlı bulduğunuzu anlamasına yardımcı olmak gibi işlevleri yerine getirir.
Compared directly to Synvisc-One®,‡4 DUROLANE reduced pain more effectively.
In a Level 1 study, there was a significantly greater reduction in visual analog scale (VAS) pain scores at 3 and 6 months with DUROLANE compared to Synvisc-One (hylan G-F 20) (p<0.001).4
- 41% lower VAS pain score at 6 months vs. Synvisc-One (hylan G-F 20).
- Only DUROLANE maintained a significant reduction vs. baseline at 6 months
‡Some patients were treated with a three-injection Synvisc® regimen. A three-injection Synvisc regimen is equivalent to one injection of Synvisc-One.
Synvisc and Synvisc-One are registered trademarks of Genzyme Biosurgery.
Delay Knee Replacement
A retrospective analysis of 50,349 US patients has shown that hyaluronic acid injections increased time to total-knee-replacement surgery in a treatment course-dependent manner.9 Patients who received ≥ 5 courses of hyaluronic acid treatment delayed total-knee-replacement surgery by 3.6 years.9
A second retrospective analysis, of 224 patients* in Spain, showed that treatment with DUROLANE increased the time to surgery of all patients up to 1.5-fold – 1093 days with DUROLANE treatment compared to 694 days without.10
*Two-hundred and two patients were treated with DUROLANE compared to 22 who did not receive DUROLANE.
Compared directly to steroids injections,*2 DUROLANE relieved pain longer.
In a Level 1 study:
- DUROLANE was proven to be noninferior to steroid at 6 weeks.†
- Results favored DUROLANE for reduction in WOMAC pain, function and stiffness scores from weeks 12 to 26.
- A significant reduction from baseline to week 26 in WOMAC pain scores was achieved with DUROLANE vs steroid.
*Effect-sizes for WOMAC domains with 95% CIs during the blinded phase of the study.
†The primary outcome was the WOMAC pain responder rate, defined as at least 40% relative improvement and 5-point absolute improvement from baseline values at 12 weeks.
Significantly Improved Quality of Life
A single injection of DUROLANE significantly improved all Knee and Osteoarthritis Outcome Score (KOOS) parameters in as early as 2 weeks, and the improvements persisted for up to 24 weeks.5